• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Voxelotor can Promote Long-Term Benefits in Teens, Adults With SCD, Latest Clinical Data Show


Global Blood Therapeutics’ lead therapeutic candidate voxelotor can induce rapid, robust, and sustained improvements in the amount of hemoglobin in adolescents and adults with sickle cell disease (SCD), according to interim results from the first part of a Phase 3 trial.

The latest results of GBT’s clinical program for voxelotor were recently presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego.

Findings from the ongoing Phase 3 HOPE trial (NCT03036813) were revealed in a presentation titled “Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031) at 24-weeks, a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease.”

The two-part study is designed to evaluate the effectiveness and safety of voxelotor in sickle cell patients ages 12 to 65.

 

https://www.onescdvoice.com/wp-content/uploads/2019/06/Voxelotor-Promote-SCD.jpg

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close